5/7/2013

Boehringer Ingelheim and Eli Lilly & Co. have launched an educational campaign for health care workers focused on sodium glucose co-transporters in support of empagliflozin, an SGLT2-inhibitor that the drugmakers developed. The campaign includes a website and a video.

Full Story:
Drug Store News

Related Summaries